Klinisk Mikrobiologi, Centrallasarettet, Växjö, Sweden.
Adelaide Medical School, University of Adelaide, Adelaide, Australia.
Clin Microbiol Infect. 2022 Jul;28(7):952-954. doi: 10.1016/j.cmi.2022.02.024. Epub 2022 Feb 24.
Identifying the MIC wild-type distribution and its delineation of species targeted for receiving antimicrobial agent breakpoints is an important first step for determining clinical breakpoints. Having the main responsibility in the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for characterizing the wild-type distributions and setting epidemiological cut-off values (ECOFFs), we explain the why, the how, and frequent misconceptions of wild-type MIC distributions and ECOFFs.
To clarify how wild-type MIC distributions and ECOFFs for agents and important target organisms are defined and determined and why these are important tools in microbiology, as well as to point to common misunderstandings and inappropriate use.
The EUCAST database of >40 000 MIC distributions; publications addressing the definition of wild-type MIC distributions, and ECOFFs in bacteria and fungi; and the EUCAST Standard Operating Procedure 10 Documents published by the European Centre for Disease Control and the European Food Safety Agency.
The rationale for defining wild-type distributions and ECOFFs is explained. Setting breakpoints that bisect wild-type MIC distributions leads to poor methodological reproducibility and poor correlation between clinical outcome and susceptibility testing results. The methods applied by EUCAST to select distributions for aggregation and website display are described, highlighting the importance of incorporating data from multiple sources and methods. The methods used by EUCAST to estimate ECOFFs are outlined. Finally, the common misunderstandings of these processes are addressed.
The international community needs to agree on the phenotypic definitions of wild-type distributions. Systematic methods for developing and applying ECOFFs are essential to the conduct of phenotypic antimicrobial susceptibility testing and interpretation, which will remain the dominant laboratory method for the foreseeable future.
确定 MIC 野生型分布及其对目标物种的划分,是确定临床折点的重要第一步。我们作为欧洲抗菌药物敏感性测试委员会(EUCAST)在表征野生型分布和设定流行病学折点值(ECOFF)方面的主要负责人,解释了野生型 MIC 分布和 ECOFF 的原因、方法和常见的误解。
阐明如何定义和确定药物和重要靶标生物体的野生型 MIC 分布和 ECOFF,以及为什么这些是微生物学中的重要工具,并指出常见的误解和不适当的使用。
EUCAST 超过 40000 个 MIC 分布数据库;涉及细菌和真菌中野生型 MIC 分布和 ECOFF 定义的出版物;以及欧洲疾病预防控制中心和欧洲食品安全局发布的 EUCAST 标准操作程序 10 文档。
解释了定义野生型分布和 ECOFF 的基本原理。将折点设定在野生型 MIC 分布的中间,会导致方法学重复性差,临床结果与药敏试验结果之间相关性差。描述了 EUCAST 用于选择聚合和网站显示分布的方法,强调了纳入来自多个来源和方法的数据的重要性。概述了 EUCAST 用于估计 ECOFF 的方法。最后,解决了这些过程的常见误解。
国际社会需要就野生型分布的表型定义达成一致。开发和应用 ECOFF 的系统方法对于表型抗菌药物敏感性测试和解释至关重要,这将在可预见的未来仍然是主导的实验室方法。